Head Diagnostics, an Irish medtech company headquartered at NovaUCD in Dublin, has signed an exclusive global licence with Philips for a digital cognitive assessment platform.
The platform enhances the ability of clinicians to detect cognitive decline at the earliest possible stage when new treatments may be most effective, the company explained.
It said it would be rebranded as HDx Cognition by Head Diagnostics.
“As cognitive impairment and dementia continue to affect millions globally, early and accessible diagnosis remains a critical unmet need,” said David van Zuydam, CEO, Head Diagnostics.
“Head Diagnostics will now integrate HDx Cognition, a clinically validated and normed cognitive and mental health testing platform, into our growing portfolio of neurotechnology solutions, empowering primary care physicians, neurologists, and hospitals to detect cognitive decline as well as mental health conditions early, accurately, and efficiently.
“This opportunity is especially urgent given the rising prevalence of neuro-related diseases with many countries such as USA, UK, France, Italy, South Korea and Japan particularly focused on improving early detection,” he added.
